<DOC>
	<DOCNO>NCT00865592</DOCNO>
	<brief_summary>The purpose study demonstrate dutogliptin/PHX1149T safe tolerable .</brief_summary>
	<brief_title>Long-term Study Evaluate Safety Dutogliptin/PHX1149T Subjects With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description>In study , open-label dutogliptin/PHX1149T offer subject complete Phase 3 core protocol wish continue treatment dutogliptin . This allow collection long-term safety data also demonstrate long-term effect HbA1c fast blood glucose .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>Completion require visit qualify Phase 3 core protocol ( e.g. , Visit 8/Day 196 PHX1149PROT301 ) Current treatment Type 2 diabetes mellitus PHX1149PROT301 Except Type 2 diabetes , uncontrolled , serious pulmonary , cardiovascular , hematologic , renal , gastrointestinal , endocrine , neurological , proliferative , immunosuppressive , psychiatric , urogenital disorder ; diseases skin appendage , eye , ear , nose , throat Any condition , disease , disorder clinically relevant laboratory abnormality , opinion investigator , would jeopardize patient 's appropriate participation study obscure effect treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>August 2010</verification_date>
	<keyword>diabetes</keyword>
	<keyword>DPP4 inhibitor</keyword>
	<keyword>dutogliptin</keyword>
	<keyword>PHX1149</keyword>
</DOC>